PE20120356A1 - Compuestos para el tratamiento de trastornos metabolicos - Google Patents
Compuestos para el tratamiento de trastornos metabolicosInfo
- Publication number
- PE20120356A1 PE20120356A1 PE2011001633A PE2011001633A PE20120356A1 PE 20120356 A1 PE20120356 A1 PE 20120356A1 PE 2011001633 A PE2011001633 A PE 2011001633A PE 2011001633 A PE2011001633 A PE 2011001633A PE 20120356 A1 PE20120356 A1 PE 20120356A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- oxadiazol
- piperidin
- halo
- acid ester
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- -1 PHENYL GROUP Chemical group 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE p ES 1 O 2; Z ES N-C(O)OR4, N-C(O)NR4R5, N-CH2-FENILO, ENTRE OTROS; A ES UN GRUPO FENILO O UN ANILLO HETEROARILO DE 6 MIEMBROS QUE CONTIENE UNO O DOS ATOMOS DE NITROGENO; B ES UN ANILLO HETEROARILO DE 5 MIEMBROS QUE CONTIENE UNO O MAS HETEROATOMOS SELECCIONADOS DE N, O Y S O UN ANILLO HETEROARILO DE 6 MIEMBROS QUE CONTIENE UNO O DOS ATOMOS DE NITROGENO; X ES O-CR6H, O, CR6H-O, ENTRE OTROS; R1 ES H, HALO, CIANO, ALQUILO C1-C4, ENTRE OTROS; q ES 1 O 2; R2 ES UN GRUPO (a) O UN GRUPO FENILO OPCIONALMENTE SUSTITUIDO CON HALO O PIRIDILO; R3 ES HALO O METILO; n ES 0 O 1; m ES 0, 1 O 2; R4 ES ALQUILO C2-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R5 ES H O ALQUILO C1-C4; R6 ES H O ALQUILO C1-C2. SON COMPUESTOS PREFERIDOS: ESTER ISOPROPILICO DEL ACIDO 4-[5-(6-CLOROPIRIMIDIN-5-IL)-[1,2,4]OXADIAZOL-3-ILMETOXI]-PIPERIDIN-1-CARBOXILICO, ESTER ISOPROPILICO DEL ACIDO 4-[3-(6-CLORO-PIRIDIN-3-IL)-[1,2,4]OXADIAZOL-5-ILMETOXI]-PIPERIDIN-1-CARBOXILICO, ESTER ISOPROPILICO DEL ACIDO 4-{(R)-1-[5-(2-CLOROPIRIMIDIN-5-IL)-[1,2,4]OXADIAZOL-3-IL]-ETOXI}-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD COMO AGONISTA DEL RECEPTOR GPR119 Y COMO INHIBIDORES DE LA DPP-IV SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS INCLUYENDO LA DIABETES TIPO II
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0904287.0A GB0904287D0 (en) | 2009-03-12 | 2009-03-12 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120356A1 true PE20120356A1 (es) | 2012-04-16 |
Family
ID=40600949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001633A PE20120356A1 (es) | 2009-03-12 | 2010-03-12 | Compuestos para el tratamiento de trastornos metabolicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120040953A1 (es) |
| EP (1) | EP2406256A1 (es) |
| JP (1) | JP2012520284A (es) |
| KR (1) | KR20110130476A (es) |
| CN (1) | CN102395584A (es) |
| AU (1) | AU2010222673A1 (es) |
| BR (1) | BRPI1009781A2 (es) |
| CA (1) | CA2754794A1 (es) |
| CL (1) | CL2011002221A1 (es) |
| EA (1) | EA201190209A1 (es) |
| GB (1) | GB0904287D0 (es) |
| IL (1) | IL215051A0 (es) |
| MA (1) | MA33242B1 (es) |
| MX (1) | MX2011009491A (es) |
| PE (1) | PE20120356A1 (es) |
| SG (1) | SG174362A1 (es) |
| WO (1) | WO2010103335A1 (es) |
| ZA (1) | ZA201107446B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149685A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
| EA201200046A1 (ru) | 2009-06-24 | 2012-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые соединения, фармацевтическая композиция и связанные с ними способы |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006167D0 (en) * | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB2488360A (en) * | 2011-02-25 | 2012-08-29 | Prosidion Ltd | Heterocyclic GPCR agonists |
| GB201114389D0 (en) * | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| WO2012066077A1 (en) * | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
| CN103958495B (zh) | 2011-06-09 | 2018-06-22 | 理森制药股份公司 | 作为gpr-119的调节剂的化合物 |
| KR101881932B1 (ko) | 2011-12-07 | 2018-07-27 | 삼성전자주식회사 | 자기 소자 및 그 제조 방법 |
| JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| BR112022000576A2 (pt) * | 2019-07-15 | 2022-05-10 | Oncoarendi Therapeutics Sa | Aminotriazóis substituídos úteis como inibidores de quitinase |
| CA3149096A1 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| WO2000012705A2 (en) | 1998-09-01 | 2000-03-09 | Basf Aktiengesellschaft | Methods for improving the function of heterologous g protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| JP5065908B2 (ja) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Ｇタンパク質結合受容体作動薬 |
| EP1838311A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| JP2008545010A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇタンパク質共役受容体アゴニスト |
| BRPI0613505A2 (pt) | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
| GB0513257D0 (en) * | 2005-06-30 | 2005-08-03 | Prosidion Ltd | Compounds |
| US20090203663A1 (en) | 2006-02-09 | 2009-08-13 | Astrazeneca Ab | Chemical compounds |
| BRPI0710839A2 (pt) | 2006-04-06 | 2011-08-23 | Prosidion Ltd | agonistas heterocìclicos de gpcr |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| MY157365A (en) | 2006-12-06 | 2016-05-31 | Smithkline Beecham Corp | Chemical compounds and uses |
| PT2114925E (pt) | 2006-12-22 | 2012-05-29 | Einstein Coll Med | Análogos de azetidina de inibidores de nucleosidase e fosforilase |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| US20100048632A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine GPCR Agonists |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| AR067568A1 (es) | 2007-07-17 | 2009-10-14 | Bristol Myers Squibb Co | Agonistas de receptor acoplado a proteina g gpr119 de piridona y una composicion farmaceutica que los contiene |
| WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| KR101136774B1 (ko) | 2007-10-18 | 2012-04-19 | 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 | 금속 피복 폴리이미드 복합체 및 그 복합체의 제조 방법 그리고 전자 회로 기판의 제조 방법 |
| CN101621337B (zh) | 2008-06-30 | 2013-08-07 | 华为技术有限公司 | 一种时延调节装置与方法 |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| EP2321308B9 (en) | 2008-07-10 | 2012-08-08 | Prosidion Limited | Piperidine gpcr agonists |
| CN102083813A (zh) | 2008-07-10 | 2011-06-01 | 普洛希典有限公司 | 哌啶基gpcr激动剂 |
| GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
-
2009
- 2009-03-12 GB GBGB0904287.0A patent/GB0904287D0/en not_active Ceased
-
2010
- 2010-03-12 SG SG2011065794A patent/SG174362A1/en unknown
- 2010-03-12 EP EP10709926A patent/EP2406256A1/en not_active Withdrawn
- 2010-03-12 JP JP2011553534A patent/JP2012520284A/ja active Pending
- 2010-03-12 AU AU2010222673A patent/AU2010222673A1/en not_active Abandoned
- 2010-03-12 MA MA34246A patent/MA33242B1/fr unknown
- 2010-03-12 WO PCT/GB2010/050442 patent/WO2010103335A1/en not_active Ceased
- 2010-03-12 CA CA2754794A patent/CA2754794A1/en not_active Abandoned
- 2010-03-12 MX MX2011009491A patent/MX2011009491A/es unknown
- 2010-03-12 BR BRPI1009781A patent/BRPI1009781A2/pt not_active Application Discontinuation
- 2010-03-12 CN CN2010800164285A patent/CN102395584A/zh active Pending
- 2010-03-12 EA EA201190209A patent/EA201190209A1/ru unknown
- 2010-03-12 KR KR1020117024020A patent/KR20110130476A/ko not_active Withdrawn
- 2010-03-12 US US13/255,536 patent/US20120040953A1/en not_active Abandoned
- 2010-03-12 PE PE2011001633A patent/PE20120356A1/es not_active Application Discontinuation
-
2011
- 2011-09-08 CL CL2011002221A patent/CL2011002221A1/es unknown
- 2011-09-08 IL IL215051A patent/IL215051A0/en unknown
- 2011-10-11 ZA ZA2011/07446A patent/ZA201107446B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012520284A (ja) | 2012-09-06 |
| ZA201107446B (en) | 2012-06-27 |
| BRPI1009781A2 (pt) | 2016-03-08 |
| CA2754794A1 (en) | 2010-09-16 |
| AU2010222673A1 (en) | 2011-11-03 |
| CN102395584A (zh) | 2012-03-28 |
| KR20110130476A (ko) | 2011-12-05 |
| WO2010103335A1 (en) | 2010-09-16 |
| IL215051A0 (en) | 2011-11-30 |
| GB0904287D0 (en) | 2009-04-22 |
| SG174362A1 (en) | 2011-11-28 |
| MX2011009491A (es) | 2011-10-11 |
| EP2406256A1 (en) | 2012-01-18 |
| CL2011002221A1 (es) | 2012-07-06 |
| EA201190209A1 (ru) | 2012-04-30 |
| US20120040953A1 (en) | 2012-02-16 |
| MA33242B1 (fr) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120356A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
| PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
| PE20110136A1 (es) | Compuestos organicos | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20090992A1 (es) | Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa | |
| PE20141681A1 (es) | Inhibidores de btk | |
| PE20110843A1 (es) | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| PE20191757A1 (es) | Compuestos heterociclicos utiles como inhibidores dobles de atx/ca | |
| RU2009148320A (ru) | Производные пиперидина/пиперазина | |
| AR087196A1 (es) | Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii | |
| EA201170522A1 (ru) | Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств | |
| MY173930A (en) | Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes | |
| NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
| SI3031799T1 (en) | Aromatic compound | |
| NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
| PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
| PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
| ATE443701T1 (de) | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |